MATTHEW W FOEHR
CIK 1237556 · President and CEO · last filed 2026-04-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$45.77M
Companies
6
Total Filings
126
Lifetime Open-Market Net
-$24.19M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OABIW | President and CEO | 4,420,492 | $0.10 | $441.6K | $7.27M | 33 | 2026-04-07 |
| VKTX | Director | 135,186 | $28.75 | $3.89M | -$286.7K | 11 | 2026-01-05 |
| LGND | President and COO | 162,187 | $255.54 | $41.45M | -$31.25M | 58 | 2022-11-03 |
| Viking Therapeutics, Inc. (VKTXW) Delisted | Director | 46,250 | $4.60 | $212.7K | -$79.9K | 8 | 2021-03-25 |
| Qualigen Therapeutics, Inc. (RTTR) Delisted | Director | 138,635 | — | — | $133.1K | 12 | 2020-04-23 |
| Viking Therapeutics, Inc. (VKTX.W) Delisted | Director | 26,250 | — | — | $24.8K | 1 | 2016-04-13 |
Recent Filings · Page 10 of 13
126 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-05-18 | Qualigen Therapeutics, Inc. (RTTR) Delisted | Buy (P) | +18,000 | $11.2K | EDGAR |
| 2017-05-15 | LGND | Mixed | +2,200 | -$552.7K | EDGAR |
| 2017-03-03 | LGND | Mixed | +2,000 | -$622.7K | EDGAR |
| 2017-02-28 | LGND | Mixed | +7,683 | -$521.2K | EDGAR |
| 2017-01-05 | Viking Therapeutics, Inc. (VKTXW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-11-30 | Qualigen Therapeutics, Inc. (RTTR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-11-15 | Viking Therapeutics, Inc. (VKTXW) Delisted | Buy (P) | +13,000 | $15.7K | EDGAR |
| 2016-08-09 | LGND | Mixed | +4,125 | -$1.36M | EDGAR |
| 2016-04-13 | Viking Therapeutics, Inc. (VKTX.W) Delisted | Buy (P) | +20,000 | $24.8K | EDGAR |
| 2016-03-17 | LGND | Mixed | +2,250 | -$532.6K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.